Arcutis Biotherapeutics (ARQT) Revenue (2022 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Revenue of $105.4 million for Q1 2026, up 65.08% year-over-year from $63.8 million in Q1 2025, and down 18.61% quarter-over-quarter from $129.5 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Revenue (2022 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Revenue history runs 5 years deep, the most recent figure standing at $105.4 million for Q1 2026.
- In Q1 2026, Revenue rose 65.08% year-over-year to $105.4 million; the TTM figure through Mar 2026 stood at $415.6 million (up 99.04% YoY), while the FY2025 annual figure was $376.1 million, up 125.81% from the prior year.
- Revenue for Q1 2026 stood at $105.4 million, down from $129.5 million in the prior quarter.
- The five-year high for Revenue was $129.5 million in Q4 2025, with the low at $725000.0 in Q3 2022.
- The 5-year median for Revenue is $43.9 million (2023), against an average of $49.3 million.
- The sharpest annual moves came in 2023 and 2024: Revenue surged 5156.41% in 2023, then rose 17.44% in 2024.
- Arcutis Biotherapeutics' Revenue stood at $3.0 million in 2022, then soared by 1384.16% to $43.9 million in 2023, then jumped by 57.83% to $69.4 million in 2024, then jumped by 86.71% to $129.5 million in 2025, then retreated by 18.61% to $105.4 million in 2026.
- Business Quant data shows ARQT's Revenue at $105.4 million in Q1 2026, $129.5 million in Q4 2025, and $99.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 129.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 129.86 Mn |
| Mar 31, 2026 | 105.40 Mn |
| Dec 31, 2025 | 129.50 Mn |
| Sep 30, 2025 | 99.22 Mn |
| Jun 30, 2025 | 81.50 Mn |
| Mar 31, 2025 | 63.85 Mn |
| Dec 31, 2024 | 69.36 Mn |
| Sep 30, 2024 | 44.76 Mn |
| Jun 30, 2024 | 30.86 Mn |
| Mar 31, 2024 | 21.57 Mn |
| Dec 31, 2023 | 43.95 Mn |
| Sep 30, 2023 | 38.11 Mn |
| Jun 30, 2023 | 4.77 Mn |
| Mar 31, 2023 | 2.78 Mn |
| Dec 31, 2022 | 2.96 Mn |
| Sep 30, 2022 | 725,000.00 |